SILO news

Silo Pharma issued a Common Stock Purchase Warrant to Norsight Consulting Inc. with an exercise price and terms set in an asset purchase agreement.

Silo Pharma filed a Form 8-K disclosing a pre-funded common stock warrant. This agreement allows the holder to purchase shares at a specified price under a securities purchase agreement.

Silo Pharma announced it regained compliance with Nasdaq's minimum closing bid price requirement as of June 17, 2026, resolving a listing qualification matter. The company continues trading on the Nasdaq Capital Market while advancing its lead PTSD drug candidate SPC-15 toward clinical trials.

Silo Pharma, Inc. filed a Certificate of Change to reduce authorized common shares from 100 million to 6.67 million through a 15-for-1 reverse stock split, with fractional shares rounded up. The restructuring is a common defensive measure to maintain exchange listing compliance and improve share pri…